Peripheral T cell lymphoma (PTCL) represents a group of heterogeneous hematological malignancies, which are notoriously challenging to treat and outcomes are typically poor. Over the past two decades, clinical prognostic indices for patient risk stratification have evolved, while several targeted agents are now available to complement combination chemotherapy in the frontline setting or as a salvage strategy. With further understanding of the molecular pathobiology of PTCL, several innovative approaches incorporating immunomodulatory agents, epigenetic therapies, oncogenic kinase inhibitors and immunotherapeutics have come to the forefront. In this review, we provide a comprehensive overview of the progress in developing clinical prognostic indices for PTCL and describe the broad therapeutic landscape, emphasizing novel targetable pathways that have entered early phase clinical studies.

中文翻译：

---

复发/难治性外周 T 细胞淋巴瘤的新型临床风险分层和治疗策略


外周 T 细胞淋巴瘤 （PTCL） 是一组异质性血液恶性肿瘤，众所周知，这些恶性肿瘤的治疗具有挑战性，而且预后通常很差。在过去的二十年里，患者风险分层的临床预后指标已经发展，而现在有几种靶向药物可用于在一线环境中补充联合化疗或作为挽救策略。随着对 PTCL 分子病理学的进一步了解，几种结合免疫调节剂、表观遗传疗法、致癌激酶抑制剂和免疫疗法的创新方法已成为前沿。在这篇综述中，我们全面概述了 PTCL 临床预后指标的开发进展，并描述了广泛的治疗前景，强调了已进入早期临床研究的新型靶向途径。